Buy & Sell YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) – YieldMax Magnificent 7 Fund of Option Income ETFs Price Today
Key Stats
- -Market Cap
- Income / Options OverlaySector
- -10.5%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 72% Buy | 28% SellTrading Activity
- 12 daysTypical Hold Time
Over the past 52 weeks, YieldMax Magnificent 7 Fund of Option Income ETFs has traded between a low of $11.51 and a high of $15.98, highlighting its annual price range. Over the past three months, YieldMax Magnificent 7 Fund of Option Income ETFs has recorded a drawdown of -10.5%, reflecting recent price volatility. On average, investors hold YieldMax Magnificent 7 Fund of Option Income ETFs for approximately 12 days, indicating typical investor behavior on the platform.
About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Most Recent News
ExxonMobil warns oil prices could spike to $160/barrel amid low inventories and geopolitical tensions.
ExxonMobil's Senior Vice President Neil Chapman warned that crude oil prices could surge to $150-$160 per barrel soon due to critically low inventory levels, despite recent price drops linked to U.S.-Iran peace talks. The company highlighted that str...

XRP shows signs of bottoming as smart money accumulates and ETFs hit best month of 2026.
XRP has shown signs of bottoming after a five-month consolidation, with smart money investors increasing accumulation. XRP ETFs recorded their best month in 2026, adding $131 million in inflows in May, contrasting with declines in Bitcoin and Ethereu...

Whitehawk reveals SEZ6 as a promising target for new cancer drug HWK-206, advancing to clinical trials in 2026.
Whitehawk Therapeutics announced data showing SEZ6 protein is highly expressed in small cell lung cancer (SCLC) and other neuroendocrine tumors, exceeding other known targets. This supports their development of HWK-206, a next-generation antibody dru...
